Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma
KSR acted as the External Assessment Group (EAG) for NICE on a recent technology appraisal: Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable [TA1195].
Dr Ceri Bygrave, Consultant Haematologist and UK Myeloma Society Advocacy Lead, said: “The substitution of lenalidomide for thalidomide will have benefit in terms of less frequent incidence of neurotoxicity and improved depth response.” She added: “Patients, carers and clinicians working in the field of myeloma have been anxiously awaiting this decision as we work towards our shared goal of finding a long‑term cure for myeloma.” [PharmaTimes; 15.9.26]
Further information can be found on the NICE website.
Photo by National Cancer Institute on Unsplash
